Department of Psychology, University of California, Los Angeles, Los Angeles, CA, United States; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, United States. Electronic address: lararay@psych.ucla.edu.
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: cberge21@jhmi.edu.
A 62-year-old woman with a history of multiple sclerosis (MS) presented with recurrent episodes of confusion, dysarthria and gait difficulties. These episodes occurred about 3 days after administratio...
Respiratory viral infections are major drivers of chronic obstructive pulmonary disease (COPD) exacerbations. Interferon-β is naturally produced in response to viral infection, limiting replication. T...
In Part 1, patients (N = 13) with stable COPD were randomised 4:1 to SNG001 or placebo once-daily for three days. In Part 2, patients (N = 109) with worsening symptoms and a positive respiratory viral...
In Part 1, SNG001 upregulated sputum interferon gene expression. In Part 2, there were minimal SNG001-placebo differences in the efficacy endpoints; however, whereas gene expression was initially upre...
Overall, SNG001 was well-tolerated in patients with COPD, and upregulated lung antiviral defences to accelerate viral clearance. These findings warrant further investigation in a larger study....
EU clinical trials register (2017-003679-75), 6 October 2017....
Multiple Sclerosis (MS) has a complex pathophysiology that involves genetic and environmental factors. DNA methylation (DNAm) is one epigenetic mechanism that can reversibly modulate gene expression. ...
The objective of this study was to determine the changes in DNAm associated with INFβ use, using methylation arrays and statistical deconvolutions on two separate datasets (total n...
We show that IFNβ treatment in people with MS modifies the methylation profile of interferon response genes in a strong, targeted, and reproducible manner. Using these identified methylation differenc...
In conclusion, our study shows that IFNβ treatment is a potent and targeted epigenetic modifier in multiple sclerosis....
Brain pseudoatrophy has been shown to play a pivotal role in the interpretation of brain atrophy measures during the first year of disease-modifying therapy in multiple sclerosis. Whether pseudoatroph...
A total of 129 patients from a prospective longitudinal multicentric national cohort study for whom magnetic resonance imaging scans at baseline, 12 months, and 24 months were available were selected ...
Patients treated with interferon-beta demonstrated accelerated annual percentage brain volume and cervical cord area change in the first year after treatment initiation, whereas atrophy rates stabiliz...
These results suggest that pseudoatrophy occurs not only in the brain, but also in the spinal cord during the first year of interferon-beta treatment....
The stimulus-induced cAMP response element (CRE)-binding protein (CREB) family of transcription factors bind to CREs to regulate diverse cellular responses, including proliferation, survival, and diff...
Treatments with interferon-beta (IFNβ) - a cytokine with established antiviral effects - were initially considered for multiple sclerosis (MS), as epidemiological data pointed towards a viral etiologi...
Fingolimod has been shown to be more effective in reducing relapse rate and disability than injectable therapies in clinical trials. An increase in N-acetylaspartate (NAA) as measured by MR spectrosco...
Ninety-eight RRMS (52 on fingolimod, 46 on injectable therapies (27 on glatiramer acetate and 19 on interferon) were age and sex-matched to 51 HCs. RRMS patients underwent cognitive, fatigue, and ment...
Clinical parameters, MR-volumetric, and neurometabolic profiles showed no differences between treatment groups (p > .05). Compared to HCs, both RRMS cohorts showed volume changes in white matter (-...
While both treatment arms showed overall similar volumetric and neurometabolic profiles, longitudinal studies are warranted to clarify neurometabolic changes and associations with treatment efficacy....
The use of glucocorticoids has given contradictory results for treating acute respiratory distress syndrome (ARDS). The use of intravenous Interferon beta (IFN β) for the treatment of ARDS was recentl...
We first sequenced the genes encoding the IFN α/β receptor of the patients, who participated in the INTEREST study (ClinicalTrials.gov Identifier: NCT02622724 , November 24, 2015) in which the patient...
We found a novel disease association of a SNP rs9984273, which is situated in the interferon α/β receptor subunit 2 (IFNAR2) gene in an area corresponding to a binding motif of the glucocorticoid rece...
The distribution of this SNP within clinical study arms may explain the contradictory results of multiple ARDS studies and outcomes in COVID-19 concerning type I IFN signaling and glucocorticoids....
Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously be...
Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as t...
A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Chan...
Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight int...
Varicella-Zoster virus (VZV) causes varicella in primary infection of children and zoster during reactivation in adults. Type I interferon (IFN) signaling suppresses VZV growth, and stimulator of inte...
